The percentage on each card is PHAT's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.
● The Motley FoolNov 18, 2026 · 15:45 ET
Phathom: 3 Key Takeaways for Long-Term Investors
Phathom reported third-quarter net revenues of $84.7 million. Commercially insured patients can access VOQUEZNA for a $0 copay through BlinkRx.…
● GlobeNewsWireNov 4, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Phathom Pharmaceuticals to Participate in November Investor Conferences
FLORHAM PARK, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) disease…
● GlobeNewsWireNov 3, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx
A Media Snippet accompanying this announcement is available by clicking on this link.…
What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call
Phathom Pharmaceuticals NASDAQ: PHAT reported third-quarter 2026 revenue growth and a second consecutive quarter of positive operating profit excluding stock-based compensation, as the company continued efforts to expand…
● Zacks Investment ResearchOct 29, 2026 · 09:36 ET
Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.07 per share. This compares to a loss of $0.15 per share a year ago.…
● GlobeNewsWireOct 29, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Over 2 million total VOQUEZNA® prescriptions filled through October 16, 2026 Q3 2026 net revenues of $84.7 million increased 71% vs. Q3 2025 and 14% vs.…
● GlobeNewsWireOct 26, 2026 · 04:00 ETCOMPANY'S OWN WORDS
Phathom Pharmaceuticals Provides Update on FDA Litigation
FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) disease…
● GlobeNewsWireOct 23, 2026 · 04:00 ETCOMPANY'S OWN WORDS
Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
FLORHAM PARK, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) disease…
● GlobeNewsWireOct 19, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026
Management to host conference call on Thursday, October 29, 2026, at 8:00 am EDT Management to host conference call on Thursday, October 29, 2026, at 8:00 am EDT…
● GlobeNewsWireOct 8, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
Three scientific presentations will highlight new analyses of VOQUEZNA® (vonoprazan) in GERD, including real-world patient characteristics, efficacy across BMI subgroups, and cost-effectiveness in Erosive Esophagitis FLO…
● GlobeNewsWireSep 29, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data Topline results expected in the first …
Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 12-Month Low – Time to Sell?
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT - Get Free Report)'s stock price hit a new 52-week low during trading on Thursday. The stock traded as low as $7.66 and last traded at $7.69, with a volume of 2071393 shares tr…
● GlobeNewsWireSep 1, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseas…
Article counts from the last market-wide feed page, across every symbol we track and not just PHAT · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.